| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cerebral Angiography | 4 | 2019 | 51 | 1.260 |
Why?
|
| Mandible | 7 | 2018 | 38 | 1.240 |
Why?
|
| Intracranial Aneurysm | 3 | 2016 | 55 | 0.960 |
Why?
|
| Tomography, X-Ray Computed | 19 | 2016 | 871 | 0.910 |
Why?
|
| Mouth Neoplasms | 7 | 2019 | 15 | 0.870 |
Why?
|
| Dental Implants | 4 | 2013 | 6 | 0.870 |
Why?
|
| Humans | 94 | 2020 | 29123 | 0.860 |
Why?
|
| Stroke | 10 | 2018 | 548 | 0.760 |
Why?
|
| Middle Aged | 46 | 2020 | 10834 | 0.730 |
Why?
|
| Defibrillators, Implantable | 1 | 2019 | 17 | 0.700 |
Why?
|
| Superior Sagittal Sinus | 1 | 2019 | 6 | 0.700 |
Why?
|
| Male | 56 | 2020 | 17815 | 0.700 |
Why?
|
| Central Nervous System Vascular Malformations | 1 | 2019 | 7 | 0.690 |
Why?
|
| Female | 54 | 2020 | 18173 | 0.690 |
Why?
|
| Adult | 37 | 2020 | 8426 | 0.690 |
Why?
|
| Models, Biological | 4 | 2016 | 373 | 0.680 |
Why?
|
| Intracranial Hemorrhages | 3 | 2017 | 32 | 0.670 |
Why?
|
| Bone Transplantation | 3 | 2013 | 47 | 0.670 |
Why?
|
| Aged | 34 | 2020 | 9492 | 0.640 |
Why?
|
| Aneurysm, Ruptured | 2 | 2016 | 26 | 0.620 |
Why?
|
| Fluoresceins | 1 | 2017 | 8 | 0.620 |
Why?
|
| Glucuronidase | 1 | 2017 | 9 | 0.620 |
Why?
|
| Intestines | 2 | 2017 | 54 | 0.610 |
Why?
|
| Fluorescent Dyes | 1 | 2017 | 45 | 0.600 |
Why?
|
| Aged, 80 and over | 20 | 2020 | 3719 | 0.600 |
Why?
|
| Bacteria | 1 | 2017 | 45 | 0.590 |
Why?
|
| Physical Conditioning, Animal | 1 | 2016 | 32 | 0.580 |
Why?
|
| Zinc | 1 | 2016 | 32 | 0.580 |
Why?
|
| Tibia | 2 | 2013 | 56 | 0.570 |
Why?
|
| Arteriovenous Fistula | 2 | 2015 | 13 | 0.570 |
Why?
|
| Adolescent | 17 | 2020 | 3255 | 0.570 |
Why?
|
| Catheter Ablation | 5 | 2013 | 62 | 0.560 |
Why?
|
| Temporomandibular Joint | 2 | 2015 | 3 | 0.560 |
Why?
|
| Maxilla | 3 | 2017 | 9 | 0.540 |
Why?
|
| Ventricular Function, Left | 1 | 2016 | 195 | 0.530 |
Why?
|
| Antineoplastic Agents | 5 | 2018 | 546 | 0.520 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2015 | 18 | 0.520 |
Why?
|
| Brain Ischemia | 6 | 2018 | 136 | 0.520 |
Why?
|
| Retrospective Studies | 21 | 2019 | 3112 | 0.500 |
Why?
|
| Finite Element Analysis | 3 | 2015 | 80 | 0.490 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2019 | 142 | 0.480 |
Why?
|
| Cerebral Arteries | 1 | 2013 | 18 | 0.470 |
Why?
|
| Fractures, Bone | 2 | 2012 | 149 | 0.470 |
Why?
|
| Cerebrovascular Disorders | 1 | 2013 | 48 | 0.460 |
Why?
|
| Kidney Neoplasms | 4 | 2013 | 192 | 0.450 |
Why?
|
| Imaging, Three-Dimensional | 8 | 2017 | 130 | 0.440 |
Why?
|
| Young Adult | 13 | 2020 | 2402 | 0.430 |
Why?
|
| Trismus | 1 | 2012 | 4 | 0.430 |
Why?
|
| Adnexal Diseases | 1 | 2012 | 6 | 0.430 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 88 | 0.410 |
Why?
|
| Radiology | 3 | 2010 | 37 | 0.400 |
Why?
|
| Animals | 20 | 2018 | 7300 | 0.400 |
Why?
|
| Treatment Outcome | 16 | 2019 | 3101 | 0.400 |
Why?
|
| Stents | 6 | 2018 | 171 | 0.390 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2010 | 7 | 0.390 |
Why?
|
| Magnetic Resonance Angiography | 5 | 2016 | 64 | 0.390 |
Why?
|
| Dental Prosthesis Design | 2 | 2013 | 2 | 0.390 |
Why?
|
| Computer-Aided Design | 1 | 2010 | 6 | 0.380 |
Why?
|
| Prognathism | 3 | 2018 | 4 | 0.370 |
Why?
|
| Apoptosis | 6 | 2019 | 337 | 0.370 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2010 | 182 | 0.360 |
Why?
|
| Osteotomy | 3 | 2018 | 49 | 0.350 |
Why?
|
| Interleukin-6 | 3 | 2017 | 225 | 0.340 |
Why?
|
| Face | 2 | 2018 | 25 | 0.320 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2018 | 152 | 0.320 |
Why?
|
| Myocardium | 3 | 2017 | 170 | 0.320 |
Why?
|
| Kidney | 4 | 2017 | 486 | 0.310 |
Why?
|
| Bacterial Proteins | 2 | 2018 | 77 | 0.310 |
Why?
|
| Thrombectomy | 2 | 2018 | 58 | 0.300 |
Why?
|
| Mice | 12 | 2018 | 2371 | 0.300 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2017 | 47 | 0.290 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2018 | 200 | 0.290 |
Why?
|
| Child | 9 | 2015 | 2219 | 0.290 |
Why?
|
| Wounds, Nonpenetrating | 2 | 2004 | 90 | 0.280 |
Why?
|
| Embolization, Therapeutic | 2 | 2019 | 79 | 0.280 |
Why?
|
| Bone and Bones | 4 | 2018 | 87 | 0.280 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2004 | 109 | 0.270 |
Why?
|
| Heart Failure | 3 | 2017 | 571 | 0.270 |
Why?
|
| Crowns | 1 | 2005 | 1 | 0.270 |
Why?
|
| Dental Prosthesis, Implant-Supported | 1 | 2005 | 1 | 0.270 |
Why?
|
| Carotid Stenosis | 1 | 2006 | 56 | 0.270 |
Why?
|
| Nanostructures | 1 | 2005 | 16 | 0.270 |
Why?
|
| Follow-Up Studies | 9 | 2018 | 2109 | 0.270 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2020 | 326 | 0.270 |
Why?
|
| Blood-Brain Barrier | 1 | 2005 | 42 | 0.270 |
Why?
|
| Patient Selection | 1 | 2007 | 257 | 0.260 |
Why?
|
| Adenoviridae | 1 | 2005 | 61 | 0.260 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2018 | 747 | 0.260 |
Why?
|
| Mice, Nude | 5 | 2018 | 276 | 0.260 |
Why?
|
| Predictive Value of Tests | 4 | 2016 | 787 | 0.260 |
Why?
|
| Genetic Vectors | 1 | 2005 | 118 | 0.260 |
Why?
|
| Lung Neoplasms | 2 | 2014 | 384 | 0.250 |
Why?
|
| Cell Line, Tumor | 9 | 2019 | 681 | 0.240 |
Why?
|
| Liver Neoplasms | 2 | 2002 | 162 | 0.240 |
Why?
|
| Postural Balance | 1 | 2016 | 160 | 0.240 |
Why?
|
| Rats | 6 | 2018 | 1604 | 0.240 |
Why?
|
| Facial Injuries | 2 | 2015 | 13 | 0.240 |
Why?
|
| Internationality | 1 | 2003 | 21 | 0.240 |
Why?
|
| Temporal Bone | 2 | 2013 | 17 | 0.240 |
Why?
|
| Hearing Loss, Sensorineural | 2 | 2013 | 20 | 0.230 |
Why?
|
| Aorta, Thoracic | 1 | 2004 | 72 | 0.230 |
Why?
|
| Myxoma | 1 | 2003 | 4 | 0.230 |
Why?
|
| Bone Density | 5 | 2012 | 182 | 0.230 |
Why?
|
| Pesticides | 1 | 2016 | 189 | 0.230 |
Why?
|
| Maxillary Sinus | 3 | 2012 | 6 | 0.230 |
Why?
|
| Heart Neoplasms | 1 | 2003 | 14 | 0.230 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2003 | 40 | 0.230 |
Why?
|
| Occupational Exposure | 1 | 2016 | 224 | 0.230 |
Why?
|
| Publishing | 1 | 2003 | 57 | 0.230 |
Why?
|
| Mitral Valve | 1 | 2003 | 28 | 0.220 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 235 | 0.220 |
Why?
|
| Enzyme Inhibitors | 2 | 2003 | 162 | 0.220 |
Why?
|
| Transients and Migrants | 1 | 2016 | 281 | 0.220 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2002 | 37 | 0.220 |
Why?
|
| Child, Preschool | 7 | 2013 | 1167 | 0.220 |
Why?
|
| Prognosis | 3 | 2016 | 1362 | 0.220 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2002 | 32 | 0.220 |
Why?
|
| Thrombolytic Therapy | 2 | 2014 | 59 | 0.210 |
Why?
|
| Periodicals as Topic | 1 | 2003 | 95 | 0.210 |
Why?
|
| United States | 6 | 2019 | 3632 | 0.210 |
Why?
|
| Taiwan | 3 | 2019 | 9 | 0.200 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 2018 | 13 | 0.200 |
Why?
|
| Radiology Information Systems | 2 | 2012 | 13 | 0.200 |
Why?
|
| Infant | 5 | 2013 | 969 | 0.200 |
Why?
|
| Limit of Detection | 2 | 2017 | 15 | 0.190 |
Why?
|
| Health Records, Personal | 1 | 2020 | 2 | 0.190 |
Why?
|
| Biological Specimen Banks | 1 | 2020 | 6 | 0.190 |
Why?
|
| Privacy | 1 | 2020 | 9 | 0.190 |
Why?
|
| Anti-Bacterial Agents | 2 | 2017 | 285 | 0.190 |
Why?
|
| X-Ray Microtomography | 4 | 2013 | 40 | 0.190 |
Why?
|
| Nanoparticles | 2 | 2018 | 48 | 0.190 |
Why?
|
| Fear | 1 | 2020 | 44 | 0.180 |
Why?
|
| Brain | 4 | 2009 | 930 | 0.180 |
Why?
|
| Patient Participation | 1 | 2020 | 62 | 0.180 |
Why?
|
| Glomerular Filtration Rate | 4 | 2017 | 287 | 0.180 |
Why?
|
| Hispanic Americans | 1 | 2016 | 904 | 0.180 |
Why?
|
| Carrier Proteins | 2 | 2014 | 131 | 0.180 |
Why?
|
| Arecoline | 1 | 2019 | 1 | 0.170 |
Why?
|
| Tissue Plasminogen Activator | 3 | 2014 | 40 | 0.170 |
Why?
|
| Drug-Eluting Stents | 1 | 2019 | 16 | 0.170 |
Why?
|
| Computer Simulation | 3 | 2013 | 207 | 0.170 |
Why?
|
| Venous Thrombosis | 3 | 2006 | 48 | 0.170 |
Why?
|
| Angiography, Digital Subtraction | 2 | 2016 | 18 | 0.170 |
Why?
|
| Orthognathic Surgical Procedures | 1 | 2018 | 2 | 0.170 |
Why?
|
| Hospices | 1 | 2018 | 5 | 0.170 |
Why?
|
| Phosphatidylethanolamines | 1 | 2018 | 2 | 0.170 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2018 | 8 | 0.170 |
Why?
|
| Antibodies, Bispecific | 1 | 2018 | 6 | 0.170 |
Why?
|
| Case-Control Studies | 4 | 2016 | 859 | 0.170 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2018 | 10 | 0.170 |
Why?
|
| Protein Multimerization | 1 | 2018 | 21 | 0.170 |
Why?
|
| Sciatica | 2 | 2016 | 3 | 0.170 |
Why?
|
| Drug Carriers | 1 | 2018 | 16 | 0.170 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2018 | 31 | 0.170 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2019 | 59 | 0.170 |
Why?
|
| Antibodies | 1 | 2018 | 53 | 0.170 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2018 | 32 | 0.170 |
Why?
|
| Polyethylene Glycols | 1 | 2018 | 66 | 0.170 |
Why?
|
| Cheek | 1 | 2018 | 5 | 0.170 |
Why?
|
| Taxoids | 1 | 2018 | 47 | 0.170 |
Why?
|
| Health Behavior | 1 | 2020 | 214 | 0.170 |
Why?
|
| Receptor, erbB-2 | 1 | 2018 | 45 | 0.160 |
Why?
|
| Neurosurgical Procedures | 1 | 2019 | 98 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2013 | 69 | 0.160 |
Why?
|
| Risk Factors | 5 | 2016 | 3537 | 0.160 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2018 | 97 | 0.160 |
Why?
|
| Cephalometry | 4 | 2018 | 18 | 0.160 |
Why?
|
| Recombinant Proteins | 1 | 2018 | 248 | 0.160 |
Why?
|
| Adiponectin | 1 | 2018 | 103 | 0.160 |
Why?
|
| Microfluidics | 2 | 2017 | 15 | 0.160 |
Why?
|
| Lung | 2 | 2014 | 233 | 0.160 |
Why?
|
| HIV Infections | 2 | 2014 | 335 | 0.160 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2009 | 1219 | 0.150 |
Why?
|
| Heart Injuries | 1 | 2017 | 8 | 0.150 |
Why?
|
| Stress, Mechanical | 4 | 2015 | 90 | 0.150 |
Why?
|
| Cerebrovascular Circulation | 2 | 2009 | 95 | 0.150 |
Why?
|
| Hydrolysis | 1 | 2017 | 38 | 0.150 |
Why?
|
| Antigens, Bacterial | 1 | 2017 | 18 | 0.150 |
Why?
|
| Mandibular Advancement | 1 | 2017 | 2 | 0.150 |
Why?
|
| Doxorubicin | 1 | 2017 | 55 | 0.150 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2017 | 9 | 0.150 |
Why?
|
| Diagnosis, Differential | 4 | 2016 | 493 | 0.150 |
Why?
|
| Molecular Imaging | 1 | 2017 | 22 | 0.150 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2014 | 57 | 0.150 |
Why?
|
| Cone-Beam Computed Tomography | 2 | 2013 | 18 | 0.150 |
Why?
|
| Escherichia coli | 1 | 2017 | 82 | 0.150 |
Why?
|
| Educational Status | 1 | 2017 | 164 | 0.150 |
Why?
|
| Endocarditis, Subacute Bacterial | 1 | 2016 | 1 | 0.150 |
Why?
|
| Staphylococcus haemolyticus | 1 | 2016 | 1 | 0.150 |
Why?
|
| Pyomyositis | 1 | 2016 | 2 | 0.140 |
Why?
|
| Phenothiazines | 1 | 2016 | 1 | 0.140 |
Why?
|
| Buttocks | 1 | 2016 | 5 | 0.140 |
Why?
|
| Arterial Occlusive Diseases | 2 | 2014 | 30 | 0.140 |
Why?
|
| Dental Prosthesis Retention | 2 | 2013 | 2 | 0.140 |
Why?
|
| Dental Implantation, Endosseous | 2 | 2013 | 4 | 0.140 |
Why?
|
| Renal Dialysis | 1 | 2019 | 260 | 0.140 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2017 | 242 | 0.140 |
Why?
|
| Rupture, Spontaneous | 1 | 2016 | 18 | 0.140 |
Why?
|
| Antipsychotic Agents | 1 | 2016 | 26 | 0.140 |
Why?
|
| Bumetanide | 1 | 2016 | 2 | 0.140 |
Why?
|
| Natriuresis | 1 | 2016 | 4 | 0.140 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2016 | 10 | 0.140 |
Why?
|
| Mandibular Nerve | 1 | 2015 | 1 | 0.140 |
Why?
|
| Tooth, Impacted | 1 | 2015 | 1 | 0.140 |
Why?
|
| Molar, Third | 1 | 2015 | 2 | 0.140 |
Why?
|
| Logistic Models | 3 | 2018 | 727 | 0.140 |
Why?
|
| Antioxidants | 1 | 2016 | 114 | 0.140 |
Why?
|
| Bicycling | 1 | 2015 | 13 | 0.140 |
Why?
|
| Sodium | 1 | 2016 | 37 | 0.140 |
Why?
|
| Subdural Effusion | 1 | 2015 | 5 | 0.140 |
Why?
|
| Drug Monitoring | 1 | 2016 | 24 | 0.140 |
Why?
|
| Regeneration | 1 | 2017 | 167 | 0.140 |
Why?
|
| Hematoma, Subdural, Acute | 1 | 2015 | 7 | 0.140 |
Why?
|
| Staphylococcal Infections | 1 | 2016 | 57 | 0.140 |
Why?
|
| Cell Proliferation | 5 | 2019 | 573 | 0.140 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 40 | 0.140 |
Why?
|
| African Americans | 2 | 2020 | 1373 | 0.130 |
Why?
|
| Mandibular Prosthesis | 1 | 2015 | 2 | 0.130 |
Why?
|
| Mandibular Condyle | 1 | 2015 | 6 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 196 | 0.130 |
Why?
|
| Myocardial Infarction | 1 | 2019 | 413 | 0.130 |
Why?
|
| Contrast Media | 2 | 2013 | 124 | 0.130 |
Why?
|
| Coal Mining | 1 | 2014 | 1 | 0.130 |
Why?
|
| Osteoclasts | 1 | 2014 | 22 | 0.130 |
Why?
|
| Posterior Cerebral Artery | 1 | 2014 | 4 | 0.130 |
Why?
|
| Morbidity | 1 | 2015 | 91 | 0.130 |
Why?
|
| Cell Hypoxia | 1 | 2014 | 39 | 0.130 |
Why?
|
| Particulate Matter | 1 | 2014 | 30 | 0.130 |
Why?
|
| Age Factors | 3 | 2018 | 1108 | 0.130 |
Why?
|
| Internship and Residency | 2 | 2009 | 283 | 0.130 |
Why?
|
| HIV-1 | 2 | 2014 | 42 | 0.130 |
Why?
|
| Aneurysm | 1 | 2014 | 21 | 0.130 |
Why?
|
| Databases, Factual | 1 | 2016 | 332 | 0.130 |
Why?
|
| Signal Transduction | 3 | 2017 | 666 | 0.120 |
Why?
|
| Magnetics | 1 | 2014 | 5 | 0.120 |
Why?
|
| Ferrous Compounds | 1 | 2014 | 6 | 0.120 |
Why?
|
| Ammonia | 1 | 2014 | 7 | 0.120 |
Why?
|
| Registries | 1 | 2015 | 278 | 0.120 |
Why?
|
| Equipment Failure Analysis | 2 | 2013 | 42 | 0.120 |
Why?
|
| Pteridines | 1 | 2013 | 1 | 0.120 |
Why?
|
| Dentistry | 1 | 2013 | 1 | 0.120 |
Why?
|
| Inflammation | 1 | 2017 | 508 | 0.120 |
Why?
|
| Ear, Inner | 1 | 2013 | 9 | 0.120 |
Why?
|
| Surface Properties | 2 | 2012 | 32 | 0.120 |
Why?
|
| Chicago | 1 | 2013 | 8 | 0.120 |
Why?
|
| False Negative Reactions | 1 | 2013 | 21 | 0.120 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 47 | 0.120 |
Why?
|
| Biomimetic Materials | 1 | 2013 | 14 | 0.120 |
Why?
|
| False Positive Reactions | 1 | 2013 | 25 | 0.120 |
Why?
|
| Point-of-Care Systems | 1 | 2014 | 33 | 0.120 |
Why?
|
| Curcumin | 1 | 2013 | 7 | 0.120 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2013 | 57 | 0.120 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2013 | 35 | 0.120 |
Why?
|
| Prospective Studies | 3 | 2016 | 2021 | 0.120 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2013 | 9 | 0.120 |
Why?
|
| Ear | 1 | 2013 | 18 | 0.120 |
Why?
|
| Dental Stress Analysis | 1 | 2013 | 1 | 0.120 |
Why?
|
| Zirconium | 1 | 2013 | 2 | 0.120 |
Why?
|
| Titanium | 1 | 2013 | 9 | 0.110 |
Why?
|
| Medical Records | 2 | 2010 | 68 | 0.110 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 207 | 0.110 |
Why?
|
| Insulin | 2 | 2013 | 346 | 0.110 |
Why?
|
| Shear Strength | 1 | 2012 | 8 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2013 | 90 | 0.110 |
Why?
|
| Bufanolides | 1 | 2012 | 1 | 0.110 |
Why?
|
| Catechin | 1 | 2012 | 5 | 0.110 |
Why?
|
| Postoperative Complications | 4 | 2013 | 670 | 0.110 |
Why?
|
| Blood Glucose | 2 | 2013 | 466 | 0.110 |
Why?
|
| Quinazolines | 1 | 2012 | 31 | 0.110 |
Why?
|
| Femur | 1 | 2012 | 67 | 0.110 |
Why?
|
| MicroRNAs | 1 | 2014 | 173 | 0.110 |
Why?
|
| Patient Access to Records | 1 | 2012 | 3 | 0.110 |
Why?
|
| Mesenteric Vascular Occlusion | 2 | 2002 | 12 | 0.110 |
Why?
|
| Cell Differentiation | 1 | 2014 | 436 | 0.110 |
Why?
|
| Protein-Lysine 6-Oxidase | 1 | 2012 | 2 | 0.110 |
Why?
|
| Sex Characteristics | 1 | 2013 | 167 | 0.110 |
Why?
|
| Copper | 1 | 2012 | 11 | 0.110 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 430 | 0.110 |
Why?
|
| Head and Neck Neoplasms | 1 | 2013 | 117 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2013 | 469 | 0.110 |
Why?
|
| Patient Preference | 1 | 2012 | 38 | 0.100 |
Why?
|
| Biphenyl Compounds | 1 | 2011 | 19 | 0.100 |
Why?
|
| Muscle, Skeletal | 1 | 2016 | 494 | 0.100 |
Why?
|
| Ductus Arteriosus | 1 | 2011 | 2 | 0.100 |
Why?
|
| Heart Aneurysm | 1 | 2011 | 3 | 0.100 |
Why?
|
| Time Factors | 5 | 2016 | 2001 | 0.100 |
Why?
|
| Structure-Activity Relationship | 2 | 2016 | 82 | 0.100 |
Why?
|
| Protein Binding | 3 | 2018 | 199 | 0.100 |
Why?
|
| Foramen Ovale, Patent | 1 | 2011 | 7 | 0.100 |
Why?
|
| Asian Continental Ancestry Group | 2 | 2017 | 110 | 0.100 |
Why?
|
| Reactive Oxygen Species | 4 | 2016 | 159 | 0.100 |
Why?
|
| Neovascularization, Pathologic | 1 | 2012 | 81 | 0.100 |
Why?
|
| Fetal Diseases | 1 | 2011 | 15 | 0.100 |
Why?
|
| Thromboembolism | 1 | 2011 | 30 | 0.100 |
Why?
|
| Facial Bones | 1 | 2011 | 10 | 0.100 |
Why?
|
| Range of Motion, Articular | 1 | 2012 | 177 | 0.100 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2011 | 89 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2004 | 337 | 0.100 |
Why?
|
| Skull Fractures | 1 | 2011 | 17 | 0.100 |
Why?
|
| Internet | 1 | 2012 | 156 | 0.100 |
Why?
|
| Neoplasms | 1 | 2017 | 611 | 0.100 |
Why?
|
| Acupuncture Analgesia | 1 | 2010 | 1 | 0.100 |
Why?
|
| Receptors, Purinergic P1 | 1 | 2010 | 7 | 0.090 |
Why?
|
| Hardness | 1 | 2010 | 5 | 0.090 |
Why?
|
| Peptide Fragments | 1 | 2013 | 422 | 0.090 |
Why?
|
| Afferent Pathways | 1 | 2010 | 23 | 0.090 |
Why?
|
| Elastic Modulus | 1 | 2010 | 24 | 0.090 |
Why?
|
| Patient Satisfaction | 1 | 2012 | 222 | 0.090 |
Why?
|
| Conscious Sedation | 1 | 2010 | 24 | 0.090 |
Why?
|
| Adenosine | 1 | 2010 | 42 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 293 | 0.090 |
Why?
|
| Anesthesia, General | 1 | 2010 | 29 | 0.090 |
Why?
|
| Prosthesis Design | 1 | 2010 | 87 | 0.090 |
Why?
|
| Molar | 2 | 2009 | 3 | 0.090 |
Why?
|
| Dentigerous Cyst | 1 | 2009 | 1 | 0.090 |
Why?
|
| Radicular Cyst | 1 | 2009 | 1 | 0.090 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2010 | 45 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2019 | 641 | 0.090 |
Why?
|
| DNA Damage | 3 | 2019 | 88 | 0.090 |
Why?
|
| Caffeine | 1 | 2009 | 31 | 0.090 |
Why?
|
| Brain Mapping | 2 | 2009 | 182 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 1362 | 0.090 |
Why?
|
| Carcinogens | 2 | 2014 | 34 | 0.090 |
Why?
|
| Cell Line | 3 | 2018 | 450 | 0.090 |
Why?
|
| Myosins | 1 | 2009 | 10 | 0.090 |
Why?
|
| Cell Survival | 3 | 2016 | 272 | 0.090 |
Why?
|
| Erythrocyte Count | 1 | 2009 | 6 | 0.090 |
Why?
|
| Severity of Illness Index | 4 | 2017 | 863 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 726 | 0.090 |
Why?
|
| Spinal Puncture | 1 | 2009 | 20 | 0.090 |
Why?
|
| Fluoroscopy | 1 | 2009 | 37 | 0.080 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2009 | 24 | 0.080 |
Why?
|
| Malocclusion, Angle Class III | 2 | 2018 | 3 | 0.080 |
Why?
|
| Central Nervous System Stimulants | 1 | 2009 | 74 | 0.080 |
Why?
|
| Cohort Studies | 5 | 2010 | 1688 | 0.080 |
Why?
|
| Catheterization | 2 | 2006 | 58 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2016 | 249 | 0.080 |
Why?
|
| Comorbidity | 3 | 2016 | 540 | 0.080 |
Why?
|
| European Continental Ancestry Group | 2 | 2017 | 1131 | 0.080 |
Why?
|
| Intracranial Thrombosis | 1 | 2008 | 8 | 0.080 |
Why?
|
| Angioplasty | 1 | 2008 | 31 | 0.080 |
Why?
|
| Kidney Diseases | 1 | 2010 | 239 | 0.080 |
Why?
|
| Work Schedule Tolerance | 1 | 2007 | 9 | 0.080 |
Why?
|
| Pain | 1 | 2010 | 282 | 0.080 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2007 | 18 | 0.080 |
Why?
|
| Equipment Design | 3 | 2017 | 167 | 0.080 |
Why?
|
| Hospitals, Teaching | 1 | 2007 | 28 | 0.080 |
Why?
|
| Postal Service | 1 | 2007 | 6 | 0.080 |
Why?
|
| Television | 1 | 2007 | 10 | 0.080 |
Why?
|
| Workload | 1 | 2007 | 38 | 0.080 |
Why?
|
| Geography | 1 | 2007 | 34 | 0.080 |
Why?
|
| Sample Size | 1 | 2007 | 37 | 0.080 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2007 | 1 | 0.080 |
Why?
|
| Tetracycline | 1 | 2007 | 11 | 0.070 |
Why?
|
| Biopsy | 3 | 2013 | 241 | 0.070 |
Why?
|
| Cytomegalovirus | 1 | 2007 | 20 | 0.070 |
Why?
|
| Transgenes | 1 | 2007 | 45 | 0.070 |
Why?
|
| Demography | 1 | 2007 | 104 | 0.070 |
Why?
|
| Recovery of Function | 1 | 2008 | 190 | 0.070 |
Why?
|
| Costs and Cost Analysis | 1 | 2007 | 88 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 3 | 2019 | 212 | 0.070 |
Why?
|
| Tacrolimus | 1 | 2007 | 44 | 0.070 |
Why?
|
| Gene Transfer Techniques | 1 | 2007 | 69 | 0.070 |
Why?
|
| General Surgery | 1 | 2007 | 81 | 0.070 |
Why?
|
| Infarction, Posterior Cerebral Artery | 1 | 2006 | 1 | 0.070 |
Why?
|
| Remission, Spontaneous | 1 | 2006 | 14 | 0.070 |
Why?
|
| Vertebral Artery | 1 | 2006 | 8 | 0.070 |
Why?
|
| Cerebral Veins | 1 | 2006 | 11 | 0.070 |
Why?
|
| Pruritus | 1 | 2007 | 58 | 0.070 |
Why?
|
| Skull | 1 | 2006 | 45 | 0.070 |
Why?
|
| Radiography | 3 | 2017 | 353 | 0.070 |
Why?
|
| North Carolina | 2 | 2016 | 1423 | 0.070 |
Why?
|
| Statistics, Nonparametric | 3 | 2011 | 129 | 0.070 |
Why?
|
| Phantoms, Imaging | 3 | 2012 | 56 | 0.070 |
Why?
|
| Analysis of Variance | 3 | 2013 | 454 | 0.070 |
Why?
|
| Cerebral Hemorrhage | 1 | 2006 | 62 | 0.070 |
Why?
|
| Denture, Partial, Fixed | 1 | 2005 | 1 | 0.070 |
Why?
|
| Jaw, Edentulous, Partially | 1 | 2005 | 1 | 0.070 |
Why?
|
| Bicuspid | 1 | 2005 | 2 | 0.070 |
Why?
|
| Osmosis | 1 | 2005 | 3 | 0.070 |
Why?
|
| Mesenteric Veins | 2 | 2002 | 5 | 0.070 |
Why?
|
| Alveolar Process | 1 | 2005 | 5 | 0.070 |
Why?
|
| Convection | 1 | 2005 | 7 | 0.070 |
Why?
|
| African Continental Ancestry Group | 1 | 2007 | 350 | 0.070 |
Why?
|
| Splints | 1 | 2005 | 13 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 167 | 0.070 |
Why?
|
| Dermatitis, Atopic | 1 | 2007 | 86 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2016 | 113 | 0.070 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2005 | 46 | 0.070 |
Why?
|
| Cadaver | 1 | 2005 | 143 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 298 | 0.060 |
Why?
|
| Mass Screening | 1 | 2007 | 223 | 0.060 |
Why?
|
| Phenylcarbamates | 1 | 2004 | 2 | 0.060 |
Why?
|
| Thoracic Diseases | 1 | 2004 | 4 | 0.060 |
Why?
|
| Urinary Calculi | 1 | 2004 | 7 | 0.060 |
Why?
|
| Tomography, Emission-Computed | 1 | 2004 | 25 | 0.060 |
Why?
|
| Neuroprotective Agents | 1 | 2004 | 20 | 0.060 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2004 | 56 | 0.060 |
Why?
|
| Fibrinolytic Agents | 2 | 2017 | 70 | 0.060 |
Why?
|
| Aortography | 1 | 2004 | 16 | 0.060 |
Why?
|
| Immunohistochemistry | 2 | 2019 | 519 | 0.060 |
Why?
|
| Radiopharmaceuticals | 1 | 2004 | 88 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 196 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2016 | 225 | 0.060 |
Why?
|
| Trauma Centers | 1 | 2004 | 84 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2003 | 72 | 0.060 |
Why?
|
| Dermatologic Agents | 1 | 2007 | 208 | 0.060 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2003 | 5 | 0.060 |
Why?
|
| Colonic Pouches | 1 | 2003 | 8 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 525 | 0.060 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2013 | 36 | 0.060 |
Why?
|
| Anastomosis, Surgical | 1 | 2003 | 49 | 0.060 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2003 | 57 | 0.060 |
Why?
|
| Colitis, Ulcerative | 1 | 2003 | 20 | 0.060 |
Why?
|
| Deoxyguanosine | 1 | 2002 | 4 | 0.060 |
Why?
|
| Nitrilotriacetic Acid | 1 | 2002 | 7 | 0.060 |
Why?
|
| Bleomycin | 1 | 2002 | 10 | 0.060 |
Why?
|
| MAP Kinase Signaling System | 2 | 2013 | 57 | 0.060 |
Why?
|
| Ferric Compounds | 1 | 2002 | 14 | 0.060 |
Why?
|
| Mutagenesis | 1 | 2002 | 32 | 0.060 |
Why?
|
| Aorta | 1 | 2003 | 103 | 0.060 |
Why?
|
| Kidney Function Tests | 2 | 2013 | 102 | 0.060 |
Why?
|
| Heart Atria | 1 | 2003 | 62 | 0.060 |
Why?
|
| Omentum | 1 | 2002 | 26 | 0.050 |
Why?
|
| Cysts | 1 | 2002 | 16 | 0.050 |
Why?
|
| Endometrial Hyperplasia | 1 | 2002 | 14 | 0.050 |
Why?
|
| Portography | 1 | 2002 | 1 | 0.050 |
Why?
|
| Ureteral Obstruction | 1 | 2002 | 29 | 0.050 |
Why?
|
| Vascular Surgical Procedures | 1 | 2003 | 91 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2002 | 62 | 0.050 |
Why?
|
| Portal Vein | 1 | 2002 | 16 | 0.050 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2002 | 19 | 0.050 |
Why?
|
| Spinal Cord Diseases | 1 | 2002 | 12 | 0.050 |
Why?
|
| Uterus | 1 | 2002 | 73 | 0.050 |
Why?
|
| Adipose Tissue | 1 | 2005 | 327 | 0.050 |
Why?
|
| Stomach Neoplasms | 1 | 2002 | 85 | 0.050 |
Why?
|
| Angiography | 1 | 2002 | 75 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2004 | 390 | 0.050 |
Why?
|
| Alzheimer Disease | 1 | 2004 | 312 | 0.050 |
Why?
|
| Sex Factors | 2 | 2013 | 631 | 0.050 |
Why?
|
| Incidence | 2 | 2015 | 1119 | 0.050 |
Why?
|
| Liver | 1 | 2002 | 464 | 0.040 |
Why?
|
| Survival Rate | 2 | 2013 | 795 | 0.040 |
Why?
|
| Peritoneal Neoplasms | 1 | 2002 | 241 | 0.040 |
Why?
|
| Absorptiometry, Photon | 2 | 2012 | 129 | 0.040 |
Why?
|
| BALB 3T3 Cells | 1 | 2018 | 1 | 0.040 |
Why?
|
| Jaw | 1 | 2018 | 3 | 0.040 |
Why?
|
| Lecithins | 1 | 2018 | 1 | 0.040 |
Why?
|
| Caspase 3 | 2 | 2012 | 30 | 0.040 |
Why?
|
| Longevity | 1 | 2018 | 22 | 0.040 |
Why?
|
| DNA Repair | 1 | 2019 | 50 | 0.040 |
Why?
|
| Cells, Immobilized | 1 | 2018 | 23 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2018 | 77 | 0.040 |
Why?
|
| Radiography, Interventional | 2 | 2013 | 35 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2020 | 153 | 0.040 |
Why?
|
| Hypertension | 1 | 2005 | 910 | 0.040 |
Why?
|
| Cerebral Infarction | 1 | 2017 | 24 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 92 | 0.040 |
Why?
|
| Fluorescence | 1 | 2017 | 21 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2018 | 165 | 0.040 |
Why?
|
| Receptors, Notch | 1 | 2017 | 16 | 0.040 |
Why?
|
| Zebrafish | 1 | 2017 | 24 | 0.040 |
Why?
|
| Automation | 1 | 2017 | 30 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2017 | 68 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2018 | 186 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2017 | 16 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 532 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2017 | 51 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2012 | 980 | 0.040 |
Why?
|
| Social Class | 1 | 2017 | 78 | 0.040 |
Why?
|
| Color | 1 | 2017 | 13 | 0.040 |
Why?
|
| Calibration | 1 | 2017 | 25 | 0.040 |
Why?
|
| Polysomnography | 1 | 2017 | 33 | 0.040 |
Why?
|
| Binding Sites | 1 | 2017 | 125 | 0.040 |
Why?
|
| Neck | 1 | 2017 | 26 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2009 | 503 | 0.040 |
Why?
|
| Caenorhabditis elegans | 1 | 2017 | 19 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2009 | 169 | 0.040 |
Why?
|
| Recurrence | 1 | 2017 | 235 | 0.040 |
Why?
|
| Disease Progression | 1 | 2019 | 572 | 0.040 |
Why?
|
| Poverty | 1 | 2017 | 99 | 0.040 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2016 | 23 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2017 | 211 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2016 | 61 | 0.040 |
Why?
|
| Sleep | 1 | 2017 | 87 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2005 | 1379 | 0.040 |
Why?
|
| Urinalysis | 1 | 2016 | 19 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2017 | 126 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2016 | 36 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 169 | 0.030 |
Why?
|
| Bite Force | 1 | 2015 | 1 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 153 | 0.030 |
Why?
|
| Acute Disease | 1 | 2016 | 239 | 0.030 |
Why?
|
| Ultrasonography | 2 | 2011 | 347 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2017 | 279 | 0.030 |
Why?
|
| Toxicity Tests, Chronic | 1 | 2014 | 3 | 0.030 |
Why?
|
| Molybdenum | 1 | 2014 | 2 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 368 | 0.030 |
Why?
|
| Silicon Dioxide | 1 | 2014 | 8 | 0.030 |
Why?
|
| Appalachian Region | 1 | 2014 | 16 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 22 | 0.030 |
Why?
|
| Speech Disorders | 1 | 2014 | 6 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2014 | 71 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2014 | 92 | 0.030 |
Why?
|
| Spectroscopy, Mossbauer | 1 | 2014 | 1 | 0.030 |
Why?
|
| Powder Diffraction | 1 | 2014 | 2 | 0.030 |
Why?
|
| Crystallization | 1 | 2014 | 16 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2019 | 518 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2014 | 82 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2014 | 31 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2013 | 6 | 0.030 |
Why?
|
| Viral Load | 1 | 2014 | 64 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2013 | 62 | 0.030 |
Why?
|
| Cell Movement | 1 | 2014 | 161 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2013 | 50 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2014 | 138 | 0.030 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2013 | 6 | 0.030 |
Why?
|
| Device Approval | 1 | 2013 | 6 | 0.030 |
Why?
|
| Iohexol | 1 | 2013 | 6 | 0.030 |
Why?
|
| Causality | 1 | 2013 | 37 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2014 | 172 | 0.030 |
Why?
|
| Autophagy | 1 | 2013 | 53 | 0.030 |
Why?
|
| Fasting | 1 | 2013 | 93 | 0.030 |
Why?
|
| Dental Materials | 1 | 2013 | 1 | 0.030 |
Why?
|
| Dental Pins | 1 | 2013 | 1 | 0.030 |
Why?
|
| Cisplatin | 1 | 2013 | 69 | 0.030 |
Why?
|
| Friction | 1 | 2013 | 4 | 0.030 |
Why?
|
| Transfection | 1 | 2013 | 192 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2013 | 44 | 0.030 |
Why?
|
| Caspase 9 | 1 | 2012 | 7 | 0.030 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2012 | 13 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 31 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2012 | 67 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 36 | 0.030 |
Why?
|
| Bone Remodeling | 1 | 2012 | 8 | 0.030 |
Why?
|
| Durapatite | 1 | 2012 | 8 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 464 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2012 | 69 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 77 | 0.030 |
Why?
|
| Torque | 1 | 2012 | 19 | 0.030 |
Why?
|
| Porosity | 1 | 2012 | 36 | 0.030 |
Why?
|
| Rats, Zucker | 1 | 2011 | 5 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2012 | 76 | 0.030 |
Why?
|
| Postprandial Period | 1 | 2011 | 10 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 637 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2012 | 158 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2012 | 66 | 0.030 |
Why?
|
| Models, Anatomic | 1 | 2012 | 38 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2011 | 125 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 199 | 0.030 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2011 | 53 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2012 | 281 | 0.020 |
Why?
|
| Wound Healing | 1 | 2012 | 182 | 0.020 |
Why?
|
| Islets of Langerhans | 1 | 2011 | 74 | 0.020 |
Why?
|
| HIV Seronegativity | 1 | 2010 | 4 | 0.020 |
Why?
|
| Uganda | 1 | 2010 | 7 | 0.020 |
Why?
|
| Mitochondria | 1 | 2012 | 174 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2011 | 136 | 0.020 |
Why?
|
| Anti-Retroviral Agents | 1 | 2010 | 21 | 0.020 |
Why?
|
| Peer Review, Health Care | 1 | 2010 | 4 | 0.020 |
Why?
|
| Nucleotidases | 1 | 2010 | 1 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2011 | 176 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2012 | 514 | 0.020 |
Why?
|
| Tooth Replantation | 1 | 2009 | 1 | 0.020 |
Why?
|
| Tooth, Nonvital | 1 | 2009 | 2 | 0.020 |
Why?
|
| Tooth, Deciduous | 1 | 2009 | 3 | 0.020 |
Why?
|
| Tooth Germ | 1 | 2009 | 2 | 0.020 |
Why?
|
| Echo-Planar Imaging | 1 | 2009 | 16 | 0.020 |
Why?
|
| Tooth Extraction | 1 | 2009 | 18 | 0.020 |
Why?
|
| Saliva | 1 | 2009 | 36 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 281 | 0.020 |
Why?
|
| Quality Control | 1 | 2009 | 38 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2009 | 106 | 0.020 |
Why?
|
| Adenosine Triphosphatases | 1 | 2009 | 11 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2011 | 599 | 0.020 |
Why?
|
| Protein Folding | 1 | 2009 | 28 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2010 | 370 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2009 | 42 | 0.020 |
Why?
|
| Actins | 1 | 2009 | 52 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2009 | 85 | 0.020 |
Why?
|
| Cerebrospinal Fluid | 1 | 2009 | 13 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 95 | 0.020 |
Why?
|
| Decompression, Surgical | 1 | 2009 | 53 | 0.020 |
Why?
|
| Needles | 1 | 2009 | 28 | 0.020 |
Why?
|
| Software | 1 | 2009 | 109 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 205 | 0.020 |
Why?
|
| Drosophila Proteins | 1 | 2009 | 43 | 0.020 |
Why?
|
| Prevalence | 1 | 2010 | 898 | 0.020 |
Why?
|
| Job Satisfaction | 1 | 2007 | 37 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 2007 | 12 | 0.020 |
Why?
|
| Emollients | 1 | 2007 | 11 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2007 | 21 | 0.020 |
Why?
|
| Sus scrofa | 1 | 2007 | 44 | 0.020 |
Why?
|
| Placebos | 1 | 2007 | 61 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 246 | 0.020 |
Why?
|
| Reference Values | 1 | 2006 | 224 | 0.020 |
Why?
|
| Gene Expression | 1 | 2007 | 332 | 0.020 |
Why?
|
| Guanine | 1 | 2005 | 14 | 0.020 |
Why?
|
| Cytosine | 1 | 2005 | 9 | 0.020 |
Why?
|
| Viscera | 1 | 2005 | 17 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2005 | 33 | 0.020 |
Why?
|
| Skin | 1 | 2007 | 203 | 0.020 |
Why?
|
| Mental Status Schedule | 1 | 2004 | 24 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2005 | 225 | 0.020 |
Why?
|
| Pericardium | 1 | 2005 | 50 | 0.020 |
Why?
|
| Nursing Homes | 1 | 2004 | 42 | 0.020 |
Why?
|
| Imidazoline Receptors | 1 | 2003 | 2 | 0.020 |
Why?
|
| Staurosporine | 1 | 2003 | 3 | 0.020 |
Why?
|
| PC12 Cells | 1 | 2003 | 7 | 0.020 |
Why?
|
| Chromones | 1 | 2003 | 6 | 0.020 |
Why?
|
| Integrin alpha5beta1 | 1 | 2003 | 2 | 0.020 |
Why?
|
| Receptor, Insulin | 1 | 2003 | 9 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 2007 | 250 | 0.020 |
Why?
|
| COS Cells | 1 | 2003 | 28 | 0.020 |
Why?
|
| Culture Media, Serum-Free | 1 | 2003 | 15 | 0.020 |
Why?
|
| Receptors, Drug | 1 | 2003 | 14 | 0.020 |
Why?
|
| Caspases | 1 | 2003 | 31 | 0.020 |
Why?
|
| Linear Models | 1 | 2005 | 426 | 0.010 |
Why?
|
| Morpholines | 1 | 2003 | 34 | 0.010 |
Why?
|
| Heart | 1 | 2005 | 162 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 97 | 0.010 |
Why?
|
| Constriction | 1 | 2003 | 12 | 0.010 |
Why?
|
| Paraplegia | 1 | 2003 | 6 | 0.010 |
Why?
|
| Genotype | 1 | 2005 | 735 | 0.010 |
Why?
|
| Anal Canal | 1 | 2003 | 16 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2004 | 379 | 0.010 |
Why?
|
| Lac Operon | 1 | 2002 | 5 | 0.010 |
Why?
|
| Mice, Inbred DBA | 1 | 2002 | 36 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2003 | 105 | 0.010 |
Why?
|
| Equipment Failure | 1 | 2002 | 22 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 2002 | 24 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2002 | 160 | 0.010 |
Why?
|
| Intubation | 1 | 2002 | 8 | 0.010 |
Why?
|
| Ultrasonography, Doppler | 1 | 2002 | 18 | 0.010 |
Why?
|
| Urinary Catheterization | 1 | 2002 | 14 | 0.010 |
Why?
|
| Myelography | 1 | 2002 | 1 | 0.010 |
Why?
|
| Punctures | 1 | 2002 | 32 | 0.010 |
Why?
|
| Aortic Aneurysm | 1 | 2002 | 12 | 0.010 |
Why?
|
| Nephrectomy | 1 | 2003 | 114 | 0.010 |
Why?
|
| Urologic Diseases | 1 | 2002 | 28 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2002 | 250 | 0.010 |
Why?
|
| Oxygen | 1 | 2002 | 139 | 0.010 |
Why?
|
| Ureter | 1 | 2002 | 35 | 0.010 |
Why?
|
| Arteriosclerosis | 1 | 2002 | 116 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2005 | 865 | 0.010 |
Why?
|
| Ischemia | 1 | 2002 | 92 | 0.010 |
Why?
|
| DNA | 1 | 2002 | 204 | 0.010 |
Why?
|
| Obesity, Morbid | 1 | 2002 | 55 | 0.010 |
Why?
|
| Endometrium | 1 | 2002 | 120 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2002 | 223 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2005 | 568 | 0.010 |
Why?
|
| Obesity | 1 | 2005 | 1063 | 0.010 |
Why?
|